A Phase 3 trial of binimetinib (MEK162) versus dacarbazine in patients with advancednras-mutant melanoma who are untreated or have progressed on or after immunotherapy

¹University Hospital Essen, Essen, Germany²Istituto Nazionale Tumori Fondazione Pascale, Naples, Italy³University Hospital Zurich, Zurich, Switzerland⁴Massachusetts General Hospital, Boston, MA, USA⁵Melanoma Institute Australia and University of Sydney, Sydney, NSW, Australia⁶Charles University, Prague, Czech Republic⁷N. N. Blokhin Russian Cancer Research Center, Moscow, Russian Federation⁸University Hospital of Siena, Siena, Italy⁹Papa Giovanni XXIII Hospital, Bergamo, Italy¹⁰Spedali Civili di Brescia, Brescia, Italy¹¹Leuven Cancer Institute, Leuven, Belgium¹²National Cancer Center Hospital, Tokyo, Japan¹³Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA